Beyond Cross-Trial Comparisons: What Digitized Survival Curves Can Really Tell Us
In today’s guest post, it’s my great pleasure to welcome Yago Garitaonaindia and Marco Donia.
The Oncology Shot with Timothee Olivier
My Personal Substack
Live Last read · last published · next check
Latest posts
Saves to your Listen queue, to pick up on another day or another device.
Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold?
Our new paper published in the European Journal of Cancer highlight current limitations regarding the efficacy of TTFs in oncology.
EMA and FDA Advocate Removing Amgen’s Drug from the Market: How Unblinded Personnel Manipulated the ADVOCATE Trial
It’s my pleasure to welcome back Sahar Van Waalwijk, who covers an important topic following an unusual development.
Additional Insights Into Early Daraxonrasib Data
Let’s take a deep dive into the early-phase data on daraxonrasib in patients with metastatic pancreatic cancer, just published in the New England Journal of Medicine.
World-first tumour-agnostic reimbursement for dual immunotherapy (ipilimumab plus nivolumab), an academic debate, and the DART trial
In two back-to-back essays, we and our counterparts reach opposing conclusions regarding the DART trial and broad reimbursement of dual immunotherapy.
RASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution?
A pharmacological breakthrough might not always revolutionize patients' outcomes.
An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.
Our new paper, with Sunny Kim and Vinay Prasad, is out in the Journal of Cancer Policy and is openly available here! Not all patients with Smoldering Myeloma will progress to Multiple Myeloma, a malignant condition.
The Chinese Immunotherapy That Passed the Dutch Test, and How To Assess What is Expected to Be a Tsunami of Immunotherapies.
The Dutch are rather picky in selecting which oncology drugs to prescribe or reimburse.
An outstanding source of trial data lacking from publications: IQWiG assessment reports. The NIAGARA trial example.
Reports from HTA bodies may contain key data absent from trial publications and constitute a unique source for trial appraisal.
My IQWiG lecture in Cologne! What a great audience and team!
I was invited by IQWiG to give a lecture in Cologne, Germany. The talk was followed by fascinating discussions with the IQWiG team about methodology in oncology trials.